Phase II study of dichloroacetate (DCA) in combination with chemoradiation (CRT) for unresected, locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).

Abstract

e17089 Background: DCA is a metabolic inhibitor that blocks pyruvate dehydrogenase kinase (PDK), which reduces tumor lactate production and may facilitate immune clearance. In vivo SCCHN mouse mode...